The Good: Blackberry Much like Gamestop below, Blackberry is seeing an amazing run, with the stock up 200%, tripling its value this year. Beguiling some investors, Blackberry seems to be surging on relatively little news. Certainly, its victory in a recent Facebook settlement started off this recent spike, but one has to dig deep into the company’s fundamentals to see why so many at-home investors are finding faith in the one-time smartphone king. After selling off its phone patents, Blackberry has repositioned itself as a security company. And the “new” Blackberry is seeing some success as it lands contracts across a variety of industries. Looking into the future, the potential goldmine is Blackberry’s connection to the burgeoning EV market and a deal with Amazon. The Bad: Gamestop For once, the bad on our list is also a type of good. Gamestop is having a legendary run over the last few weeks, following news including a new CEO and an increased faith in digital. But the run, which saw the stock up 80% on Friday and up another 50% today before closing up over 20%, has largely been pushed by piling-on from at-home investors. From Reddit’s Wall Street Bets to the many Robinhood traders, the stock is being bought in an attempt to beat the many professionals who have Gamestop shorted. While these numbers are absolutely impressive, part of the potential problem is the volatility as seen in the last couple of weeks, mixed with the allure of big-money bringing in rookie investors. The stock is one to watch, either as a diamond investment or a potential collapse. The Ugly: Merck, Moderna, and Vaccine Makers It seems like just last week we were all feeling a bit more hopeful about getting some relief from Covid thanks to a ramped up vaccine schedule, a new administration at the helm of things and an enlivened Dr. Fauci. But a series of setbacks across the vaccine spectrum have doused hopes, sending the markets into a dip. First, Merck abandoned its two pending vaccines, slimming the potential field of distributable vaccines. Then, Moderna announced its two-part vaccine would require a booster to combat the new, more-transmissible strain of the virus which recently was located in South Africa, complicating distribution plans thoroughly. Some hope exists on the horizon in the form of the Johnson and Johnson one shot vaccine.